Hyperglycemia
Drug research and approvals for hyperglycemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 139 studies of hyperglycemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 139
- Trials authorized in Canada: 2
- FDA orphan approvals: 1
- EU medicines: 0
Recruiting now
Newest start dates first, of 139 recruiting on ClinicalTrials.gov ↗- Fulvic Acid Supplementation and Metabolic SyndromeNCT07927283 · Not applicable · Arizona State University · starts Nov 6, 2026
- Food-i-Sense Analytics: Integrating AI Into Continuous Glucose Monitoring Data Analysis for Precision Nutrition.NCT07626658 · Not reported · IMDEA Food · starts Oct 15, 2026
- Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk AdultsNCT07575438 · Phase 2 · May Faraj, PDt, PhD · starts Oct 5, 2026
- Hypothalamic GLP-1 Response in Healthy Weight and ObesityNCT07854886 · Not applicable · University of Copenhagen · starts Oct 1, 2026
- Maltodextrin Versus Sugar Water Carbohydrate Loading and Gastric Volume in Geriatric Lower Limb Orthopedic SurgeryNCT07872683 · Not applicable · Udayana University · starts Sep 27, 2026
- Real-time Engagement for Learning to Effectively Control Type 2 DiabetesNCT06375460 · Not applicable · University of Pittsburgh · starts Sep 20, 2026
- The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic HealthNCT07760506 · Not applicable · Applied Science & Performance Institute · starts Sep 18, 2026
- Risk-informed Shared-decision Making Engagement Strategy for Patients With PrediabetesNCT07553325 · Not applicable · Johns Hopkins University · starts Aug 7, 2026
- HbA1c Screening in Dental Care and Primary Care Referral in Patients With Advanced PeriodontitisNCT07688278 · Not applicable · Region Skane · starts Jul 1, 2026
- PREdiabetes GLycemic Impact and Data EvaluationNCT07599072 · Not applicable · Nazarii Kobyliak · starts Jul 1, 2026
Drug pipeline
7 in phase 3, 4 in phase 2, 6 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Insulin human
- Phase 3 Insulin receptor agonist
- Insulin pork
- Phase 3 Insulin receptor agonist
- Insulin lispro
- Phase 3 Insulin receptor agonist
- Insulin susp isophane recombinant human
- Phase 3 Insulin receptor agonist
- Liraglutide
- Phase 3 Glucagon-like peptide 1 receptor agonist
- Insulin glargine
- Phase 3 Insulin receptor agonist
- Ginseng, american
- Phase 3
- Exenatide
- Phase 2 Glucagon-like peptide 1 receptor agonist
- Pasireotide
- Phase 2 Somatostatin receptor 5 agonist
- Lanreotide
- Phase 2 Somatostatin receptor 5 agonist
- Insulin susp isophane semisynthetic purified human
- Phase 2 Insulin receptor agonist
- Volagidemab
- Phase 1 Glucagon receptor inhibitor
- LY-2608204
- Phase 1 Hexokinase type IV activator
- Orforglipron
- Phase 1
- Macupatide
- Phase 1
- Honey
- Early phase 1
- Dichloroacetic acid
- Early phase 1
How its trials ended
646 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 126 whose ending is known, 50% met their primary endpoint, 11% missed it and 39% stopped early.
- Completed, result not reported32751%
- Ongoing11117%
- Status unknown8213%
- Met its primary endpoint6310%
- Stopped: other or unclear264%
- Stopped: enrollment or feasibility183%
- Missed its primary endpoint142%
- Stopped: safety20%
- Stopped: lack of efficacy10%
- Stopped: sponsor or business decision10%
- Stopped: funding10%
Trials authorized in Canada
Newest first; search them all in Canada trials| Feb 28, 2020 | Adolescent type 1 diabetes treatment with SGLT2I for hyperglycemia & hyperfiltration trialDapagliflozin | Hospital for Sick Children | Closed |
| Jun 22, 2018 | Open study to evaluate the efficacy and safety of metformin in individuals with fragile x syndromeMetformin | Dr Artuela Caku | Ongoing |
FDA orphan designations
Approved first, then open designations, newest first| Feb 17, 2012 | KorlymFor the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2… | Corcept Therapeutics, Inc. | Approved |
| Mar 28, 2018 | FluasteroneTreatment of Cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis) | Sterotherapeutics, LLC | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA